Patients’ needs
propel us forward

Our mission & values

We are on a mission to harness the microbiome to transform the lives of patients. To achieve our mission, we have assembled a team of multi-disciplinary experts and built a culture that values collaboration and a diversity of perspectives and ideas. Our team is united by our collective desire to develop a novel class of therapeutics for patients and families battling serious conditions linked to disruption of the microbiome.

Built into our company DNA is a strong commitment to living our core values and utilizing them to guide our decisions and actions.

Patients first

We have an unwavering commitment to putting the needs of patients first in everything we do


We work relentlessly to achieve our mission and deliver on our commitments


We maintain open minds and constantly work to expand our knowledge


We push scientific boundaries and ourselves


We are committed to nurturing a strong, diverse community within Finch and giving back to the external communities we are a part of

Our leadership team

Our leadership team is comprised of seasoned biotech executives and recognized leaders in the microbiome field—clinicians and scientists that have paved the way for a new class of therapeutics with the potential to treat a wide range of conditions linked to disruption of the microbiome. Our leadership team combines decades of experience in the areas of microbiology, data science, clinical research, and the manufacture and commercialization of complex biologics.

Card image cap

Mark Smith, PhD

Chief Executive Officer

Card image cap

Marc Blaustein

Chief Operating Officer

Card image cap

Alka Batycky, PhD

Chief Development Officer

Card image cap

Howard Franklin, MD, MBA

Interim Chief Medical Officer

Card image cap

Joseph Vittiglio, JD

Chief Business and Legal Officer

Card image cap

Sonia Timberlake, PhD

Senior Vice President, Research

Card image cap

Bryan Gillis, MBA

Chief Technology Officer

Card image cap

Jim Sigler, MBA

Executive Vice President of CMC

Card image cap

James Burgess

Vice President, Innovation

Card image cap

Irina Koroleva, PhD

Vice President, Translational Medicine

Card image cap

Mitch Jones, MD, PHD

Vice President, Clinical Discovery and Development

Card image cap

Matt Nelson, MBA

Vice President, Finance

Our board of directors

Our Collaborators

We believe that collaboration is key to unlocking the full potential of the microbiome. As such, we have partnerships with leading clinician researchers and institutions driving human microbiome research around the globe—from the United States to Australia and China.

We are also proud to partner with Takeda Pharmaceuticals on the development of microbiome therapeutics for individuals with ulcerative colitis and Crohn’s disease, the most common types of inflammatory bowel disease (IBD). Our partnership, initially focused on the development of TAK-524 (previously known as FIN-524) for ulcerative colitis, was expanded in 2019 to include the initial development of a potential microbiome product candidate, FIN-525, for Crohn’s disease. Takeda’s deep expertise in gastroenterology and IBD is an ideal complement to our own expertise in microbiome therapeutics.

Collaborate with us

We actively partner with academic researchers to catalyze discoveries in the microbiome. Please reach out to us if you would like to explore opportunities to work together.

Contact us

To read more about our collaboration with Takeda:

Finch Therapeutics Announces Takeda to Accelerate Leadership Role in FIN-524 Ulcerative Colitis Development Program


Finch Therapeutics & Takeda Expand Collaboration to Develop Microbiome Therapeutics Using Finch’s Human-First Discovery Platform


Finch Therapeutics and Takeda Announce Global Collaboration to Develop Microbiome Therapeutics in Inflammatory Bowel Disease


Key milestones in the field & Finch’s history

4th century

  • First written accounts emerge from China of therapeutic applications of microbial therapies.


  • Ben Eiseman et al. publishes first report of four patients with pseudomembranous enterocolitis treated with microbiota transplantation.


  • Anna Schwan et al. publishes first report of C. difficile infection treated with microbiota transplantation.


  • Thomas Borody, founder of the Centre for Digestive Diseases in Australia, begins treating patients with microbiota transplantation and subsequently publishes 59 case reports describing the use of this novel approach for a variety of different conditions, such as ulcerative colitis and Crohn’s disease. Borody goes on to carry out thousands of microbiota transplantations and his work will help catalyze microbiome research around the world.


  • Thomas Borody begins to evaluate the use of microbiota transplantation for children with autism, helping to spur further research exploring the role of the microbiome in autism.


  • The NIH launches the Human Microbiome Project to enable comprehensive characterization of the human microbiome and analysis of its role in human health and disease.


  • Thomas Borody files for patents covering stable, orally administered microbiome therapeutics, laying the groundwork for what will become Finch’s leading intellectual property portfolio.


  • Thomas Borody founds CIPAC, which later becomes Crestovo, to deliver a new generation of microbiome therapeutics for patients.
  • Alex Khoruts and Michael Sadowsky from the University of Minnesota file for patents that cover the preservation and oral delivery of complete microbiome communities, technology that Finch will later license and further develop to address conditions linked to microbiome disruption.


  • Eric Alm from MIT publishes one of the first reports of supervised machine learning applied to the human microbiome, laying the cornerstone for the future development of Finch’s machine-learning based platform.
  • A group of MIT graduate students start the nation’s first public stool bank, OpenBiome, after witnessing a family friend struggle to find a safe and effective treatment for recurrent C. difficile. OpenBiome’s founders will later start Finch to further scale their efforts to harness the therapeutic potential of the microbiome.


  • Els van Nood et al. publish first randomized controlled trial of microbiota transplantation for recurrent C. difficile. Results show a significant benefit compared to placebo, with the trial stopped early for benefit.


  • Finch Therapeutics is formed to harness the genomic revolution and machine learning to pioneer microbiome therapeutics.


  • Zain Kassam co-authors the publication of the first randomized controlled trial of microbiota transplantation for ulcerative colitis. This group and others demonstrate that microbiota transplantation has a significant benefit compared to placebo, paving the way for the future development of Finch and Takeda’s program in ulcerative colitis.


  • Christopher Staley et al. publish positive results from an open label, Phase 1 study of CP101 for recurrent C. difficile, paving the way for the further development of what will become Finch’s lead candidate.
  • Finch and Takeda announce collaboration to develop a novel microbiome therapeutic for ulcerative colitis leveraging Finch’s machine-learning based platform.
  • Jim Adams, Tom Borody and other researchers co-author an open label study of microbiota transplantation for children with autism and gastrointestinal symptoms. This group and others show improvements in gastrointestinal and behavioral symptoms following microbiota transplantation, laying the groundwork for Finch’s FIN-211 program in autism.
  • Finch merges with Crestovo to form a leading microbiome therapeutics platform.


  • Finch and Takeda expand their collaboration, with the parties agreeing to leverage Finch’s machine-learning based platform to target the development of a novel microbiome therapeutic for Crohn’s disease.


  • Finch reports positive topline data from its Phase 2 trial of CP101 for recurrent C. difficile, marking the first positive pivotal trial in the field with an orally administered microbiome product candidate.


  • Finch announces that Takeda will accelerate its leadership role in advancing the FIN-524/TAK-524 ulcerative colitis development program. The transition will enable Takeda to leverage its expertise in inflammatory bowel disease throughout the clinical development of FIN-524/TAK-524.
  • Finch reports positive topline data from its Phase 2 open-label trial of CP101, adding to the growing body of evidence supporting CP101 for the prevention of recurrent C. difficile in adults.

Contact us

General inquiries:

[email protected]


[email protected]

Investor inquiries:

[email protected]

Media inquiries:

[email protected]

Our office:

200 Inner Belt Road, Suite 400
Somerville, MA, 02143
T: 617-229-6499

Follow us